Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Astrazeneca wants Gilead; or does it?
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Joint makers report pandemic pain
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Immatics and Molmed become the subjects of very different deals
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
CD47 is worth $4.9bn to Gilead
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Iovance bulls should focus on execution
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.
